ThromboGenics’ ocriplasmin (Jetrea) has received a positive Common Drug Review (CDR) in Canada.
Leuven, Belgium-ThromboGenics’ ocriplasmin (Jetrea) has received a positive Common Drug Review (CDR) in Canada.
The CDR, which is carried out by the Canadian Agency for Drugs and Technologies in Health, is a pan-Canadian process for conducting objective, rigorous reviews of the clinical, cost-effectiveness, and patient evidence for drugs. CDR also provides formulary-listing recommendations to Canada’s publicly funded drug plans, except Quebec.
Ocriplasmin is already covered by most of the major private payers in Canada.
“I am pleased that (ocriplasmin) has received a positing CDR in Canada,” said Patrik De Haes, MD, chief executive officer of ThromboGenics. “Today, only 30% of all first-in-class products have received a positive CDR listing recommendation. This follows and confirms positive outcomes with the reimbursement agencies in the United Kingdom and Germany.
“I believe (the) CDR review and recognition of the clinical and economic value of this novel treatment for symptomatic vitreomacular traction augurs well for the future success of (ocriplasmin),” Dr. De Haes added.
For more articles in this issue of Ophthalmology Times eReport, click here.
To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.